Navigation Links
Northwestern Memorial Hospital's Steven J. Stryker MD Unveils Campaign With Empower Public Relations
Date:2/25/2008

CHICAGO, Feb. 25 /PRNewswire/ -- Dr. Steve Stryker gastrointestinal surgeon and founder of Digestique has appointed Empower Public Relations to help spread the message about diagnosing and treating digestive diseases in women. The board certified physician is currently a Professor of Clinical Surgery at Northwestern University Feinberg School of Medicine and is widely recognized for his expert diagnosis of often ignored gastric symptoms.

Located at 680 N. Lake Shore, Digestique offers an array of services ranging from comprehensive evaluations to more focused investigations.

CEO of Empower PR Sam Chapman states, "Dr. Steve Stryker is devoted to helping women of all ages improve their quality of life. He is a renowned doctor in the city of Chicago and it is an honor to represent him."

ABOUT DR. STEVEN STRYKER:

Dr. Stryker has devoted his entire career, spanning more than two decades, to the diagnosis and treatment of gastrointestinal disorders. His medical degree is from Northwestern University and his surgical internship and residency were undertaken at Northwestern Memorial Hospital in Chicago. Dr. Stryker is currently Professor of Clinical Surgery at Northwestern University Feinberg School of Medicine. He is board certified by both the American Board of Surgery and the American Board of Colon and Rectal Surgery. Dr. Stryker is widely recognized as an expert in the treatment of gastrointestinal diseases and has extensively published on these subjects. He has just recently opened the Digestique clinic, exclusively for the diagnosis and management of chronic digestive disorders in women.

ABOUT EMPOWER PUBLIC RELATIONS:

Empower Public Relations is one of Chicago's most accomplished PR firms, with a focus on television appearances. Empower has clients in a variety of industries, ranging from the nation's leading sex therapist, Space Command's "Stress Doctor," and ultra-premium liquor brands. Clients have appeared on the
'/>"/>

SOURCE Empower Public Relations
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Northwestern Memorial HealthCare and Northwestern Memorial Foundation Elect New Members to Board of Directors
2. Northwestern Memorials Heart Center Pioneers Minimally Invasive Surgery That Corrects Irregular Heart Beat
3. Royalty Pharma Acquires a Portion of Northwestern Universitys Royalty Interest in Lyrica(R) for $700 Million
4. Northwestern University and ACORN Commence National Enrollment for Metastatic Breast Cancer Study
5. Northwestern exposing most deadly infectious diseases in 3-D
6. Northwestern Memorial Hospital Completes Move Into Its New Prentice Womens Hospital
7. Physician Team at Northwestern Memorial Performs Rare Oral Gallbladder Removal
8. Evanston Northwestern Healthcare Wins Award For Patient Safety
9. Otho S.A. Sprague Memorial Institute awards Rush nearly $125,000 for new patient-safety project
10. Otho S.A. Sprague Memorial Institute awards Rush $230,000 for childhood obesity prevention
11. MemorialCare Medical Centers CEO Barry Arbuckle Elected Chair of California Hospital Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...ert Pathologists Discuss the Latest Developments i...RTHFIELD, Ill., Sept. 5 /PRNewswire-USNewswire/ --...point. Molecular testing and the promise,of person...reated. Digital,slides and other imaging technolog...lege of American Pathologists is taking a leadersh...
(Date:9/5/2008)...hers explain how theoretical ,anti-cloak, could br...pt. 5 (HealthDay News) -- Just in case someone dev...cientists say they know how to uncloak the objects... Optics Express , certain materials underneath an ...o be seen again. , Researchers at Shanghai Jiao...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- Speake...y in support of the aims of the "Stand,Up to Cance... "There is not a person in our country who has no...r kills 565,000 Americans annually, and each,year ...ricans must work,together to make eradicating the ...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- U.S. c...r relief to Cuban victims of Hurricane,Gustav, whi...s., (http://www.PanAmericanRelief.org ), "Donatio...perately need,after this natural disaster," says M... Initiative at the Pan American Development Founda...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:Cuban Disaster Relief Donations Sought in the Wake of Hurricane Gustav 2
...rned patients on anti-depressants against taking w...lth's Medicines and Healthcare products Regulatory... of psychiatric reactions to drug, marketed as Aco...364) psychiatric reactions have been reported," it...
...crore Indian health insurance industry is poised t...wth rate of over 44 per cent per annum, it is one ...urers and even life insurers are jumping in the fr... Corporation of India (LIC), for instance, is pla...
..., for her upcoming tour bosses have asked her to s...he gig is over . According to a source, although ...by soon, she was bugged by the contract as no othe... to sign such contract. Its just a practical requ...
...rks about her, claiming that the actress is too ol...utcher tied the knot in September 2005, and the ac...by. Lesley Guynes, who is separated from Moores h...hat the 44-year-old actress was unable to have kid...
Other Medicine News:Health News:UK Reports Psychiatric Reactions to Weight-loss Drug Rimonabant 2Health News:Life Insurers in India to Launch Health Insurance Policies 2
(Date:9/4/2008)...stralia, Sept. 4 /- Cytopia Limited (...rolment for its Phase Ib/II,study of CYT997, the c...t,in patients with an aggressive form of brain ca... GBM clinical trial is the first Phase II efficacy... for the company and the second in its,suite of Ph...
(Date:9/4/2008)...ished in ,The Lancet, and Presented at ESC Congres... from a new international,study, the GISSI Heart F...,omega-3 acid ethyl esters reduced all cause morta...asons in patients with chronic heart,failure. Thes...sion of ,The,Lancet, and were presented at the Eur...
(Date:9/4/2008)...erland, September 4 /- Axentis Pharma...sess the safety and tolerability,of a new therapeu...ary,infection in cystic fibrosis patients. The new...nt to be delivered directly to the site of,infecti...fects of two,different doses of the new drug. Init...
(Date:9/4/2008)...ents Remain on Schedule with Two Abstracts Accepte...lease in November 2008, BRIDGEWATER, N.J., Sept. ...a specialty pharmaceutical company focused on the ... today announced the appointment of,Peter L. Garra...Peter Garrambone,s career includes more than 50 ph...
Breaking Medicine Technology:Cytopia Commences Second Phase II Study in Brain Cancer 2Cytopia Commences Second Phase II Study in Brain Cancer 3New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 2New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 3New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 4Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 2Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 3Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 4Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2URAC Releases Standards and Measures for Wellness Programs for Public Comment 22608 1URAC Releases Standards and Measures for Wellness Programs for Public Comment 22608 2URAC Releases Standards and Measures for Wellness Programs for Public Comment 22608 3URAC Releases Standards and Measures for Wellness Programs for Public Comment 22608 4URAC Releases Standards and Measures for Wellness Programs for Public Comment 22608 5Keryx Biopharmaceuticals to Present at the Jefferies 26 Co Healthcare Conference 6180 1Keryx Biopharmaceuticals to Present at the Jefferies 26 Co Healthcare Conference 6180 2New Generation Biofuels Set to Join Russell Microcap Index 6178 1New Generation Biofuels Set to Join Russell Microcap Index 6178 2New Generation Biofuels Set to Join Russell Microcap Index 6178 3Astellas Launches Lexiscan 28TM 29 28Regadenoson 29 Injection for Use as a Pharmacologic Stress Agent in Radionuclide Myocardial Perfusion Imaging 2 6176 1Astellas Launches Lexiscan 28TM 29 28Regadenoson 29 Injection for Use as a Pharmacologic Stress Agent in Radionuclide Myocardial Perfusion Imaging 2 6176 2Astellas Launches Lexiscan 28TM 29 28Regadenoson 29 Injection for Use as a Pharmacologic Stress Agent in Radionuclide Myocardial Perfusion Imaging 2 6176 3
...reated with VELCADE, cyclophosphamide,and prednis...7 /PRNewswire-FirstCall/ -- Millennium,Pharmaceuti...esults,from clinical trials of VELCADE based thera...e response(1) (CR) rates in previously,treated mul...resented at the prestigious 11th International Mye...
... Greece, June 29, 2007 /PRNewswire/ --,The Europea...viously treated patients on REVLIMID (lenalidomide...ival of 35 months, nearly,three years. The data ar...e III trials that enrolled more than 700 patients,...dated results,were presented at the 11th Internati...
Other Medicine Technology:Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 2Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 3Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 4Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 5Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 6The European Myeloma Platform Reports New Survival data for,Revlimid Presented at the International Myeloma Workshop in Greece 2
...demand environments like OB/GYN, ER/Trauma, ICC/CC... delivers precision and control, plus consistent h...FESKIN* SATIN PLUS* Sterile Singles delive...excellent tactile sensitivity. The gloves are powd...
UROLOGY DRAPE. Soft translucent material for excellent shape conformity. Latex finger cot with additional adhesive ring around base. Full-width 50mm adhesive strip for secure fixing, with finger lift
NEAR-SkinTM Incise Drape Aggressive adhesive with no residue High moisture permeability for extended adhesion Low-glare matte finish film Product number identification
...the Penilab IV and the Penilab V have an exception...al studies. Model 1060 is similar to the Model 10...can one be added later. The Penilab V has a Doppl...of the accessories you'll need to get started. La...
Medicine Products: